Finpecia: Clinically Proven Hair Regrowth Treatment
Finpecia
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $4.00 | $40.00 (0%) | 🛒 Add to cart |
| 20 | $2.50 | $80.00 $50.00 (38%) | 🛒 Add to cart |
| 30 | $2.00 | $120.00 $60.00 (50%) | 🛒 Add to cart |
| 60 | $1.17 | $240.00 $70.00 (71%) | 🛒 Add to cart |
| 90 | $1.00 | $360.00 $90.00 (75%) | 🛒 Add to cart |
| 120 | $0.83 | $480.00 $100.00 (79%) | 🛒 Add to cart |
| 180 | $0.61 | $720.00 $110.00 (85%) | 🛒 Add to cart |
| 270 | $0.56 | $1080.00 $150.00 (86%) | 🛒 Add to cart |
| 360 | $0.49
Best per pill | $1440.00 $175.00 (88%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $5.00 | $50.00 (0%) | 🛒 Add to cart |
| 20 | $3.00 | $100.00 $60.00 (40%) | 🛒 Add to cart |
| 30 | $2.33 | $150.00 $70.00 (53%) | 🛒 Add to cart |
| 60 | $1.33 | $300.00 $80.00 (73%) | 🛒 Add to cart |
| 90 | $1.11 | $450.00 $100.00 (78%) | 🛒 Add to cart |
| 120 | $0.92 | $600.00 $110.00 (82%) | 🛒 Add to cart |
| 180 | $0.78 | $900.00 $140.00 (84%) | 🛒 Add to cart |
| 270 | $0.74 | $1350.00 $200.00 (85%) | 🛒 Add to cart |
| 360 | $0.67
Best per pill | $1800.00 $240.00 (87%) | 🛒 Add to cart |
Finpecia is a prescription medication containing the active ingredient finasteride, specifically formulated to address androgenetic alopecia (male pattern hair loss) in men. It functions as a selective inhibitor of Type II 5α-reductase, an enzyme responsible for converting testosterone to dihydrotestosterone (DHT). By significantly reducing serum and scalp DHT levels—a key driver of follicular miniaturization—Finpecia helps halt hair loss progression and promotes regrowth in a majority of treated patients. It is intended for use by adult men only and requires consistent daily administration to achieve and maintain optimal results.
Features
- Contains 1mg of finasteride per tablet
- Oral administration; one tablet daily
- Selective Type II 5α-reductase inhibition
- Reduces scalp DHT by up to 60%
- Manufactured under strict pharmaceutical standards
- Bioequivalent to brand-name formulations
Benefits
- Effectively slows or stops the progression of hair loss in vertex and anterior mid-scalp areas
- Promotes visible hair regrowth in clinical studies, with 66% of men showing improvement after two years
- Prevents further follicular miniaturization by addressing the hormonal root cause
- Non-surgical, convenient daily oral treatment
- Helps improve hair density and coverage over time
- May enhance patient self-esteem and quality of life related to appearance
Common use
Finpecia is indicated for the treatment of male pattern hair loss (androgenetic alopecia) in men aged 18 years and older. It is most effective for hair loss occurring at the crown and mid-scalp areas. Clinical studies demonstrate that Finpecia increases hair count and improves hair appearance in the majority of patients who use it consistently. Treatment response is typically evaluated after at least three months of continuous use, with optimal results often observed after 6-12 months. The medication is intended for long-term use, as discontinuation will lead to a reversal of benefits within 12 months.
Dosage and direction
The recommended dosage is one 1mg tablet taken orally once daily, with or without food. Tablets should be swallowed whole with a glass of water. For optimal absorption and consistency, take Finpecia at approximately the same time each day. Treatment should continue for as long as benefits are desired, as cessation will lead to a gradual return to pretreatment hair loss patterns within 6-12 months. Dosage adjustment is not typically required for elderly patients or those with renal impairment, though hepatic impairment may warrant careful monitoring.
Precautions
Prior to initiating treatment, patients should have a confirmed diagnosis of androgenetic alopecia. Women who are or may potentially be pregnant must not handle crushed or broken Finpecia tablets due to risk of absorption through the skin and potential teratogenic effects on a male fetus. Patients should be monitored for any changes in sexual function, including libido, erection, and ejaculation disorders. Regular follow-up evaluations are recommended to assess treatment efficacy and tolerability. Those with liver function abnormalities should use Finpecia with caution and undergo periodic liver function tests.
Contraindications
Finpecia is contraindicated in the following populations: women who are pregnant or may become pregnant due to risk of fetal abnormalities; pediatric patients; patients with hypersensitivity to finasteride or any component of the formulation; and patients with pre-existing severe hepatic impairment. The medication must not be used by women of childbearing potential unless they are using highly effective contraception and understand the potential risks.
Possible side effects
The most frequently reported adverse reactions involve sexual function, including decreased libido (1.8%), erectile dysfunction (1.3%), and ejaculation disorders (1.2%). These effects typically resolve in men who discontinue treatment and in many who continue therapy. Less common side effects may include breast tenderness and enlargement, hypersensitivity reactions (including rash, itching, hives, and swelling of the lips and face), and testicular pain. Post-marketing reports have described depression, though a causal relationship has not been established. Most adverse effects are mild and reversible upon discontinuation.
Drug interaction
Finpecia has no clinically significant interactions with medications metabolized by the CYP450 enzyme system. However, caution is advised when co-administering with potent CYP3A4 inhibitors such as ketoconazole, itraconazole, or ritonavir, as they may increase finasteride exposure. No meaningful interactions have been observed with terazosin, warfarin, digoxin, propranolol, theophylline, or oral contraceptives. Patients should inform their healthcare provider of all medications, including over-the-counter drugs and herbal supplements.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed tablet. Consistent daily dosing is important for maintaining stable DHT suppression and optimal treatment efficacy.
Overdose
Single doses of finasteride up to 400mg and multiple doses up to 80mg/day for three months have been administered without significant adverse effects. In case of suspected overdose, symptomatic and supportive treatment should be initiated. Finasteride is not dialyzable. Medical attention should be sought if unusually large quantities are ingested, though no specific antidote exists.
Storage
Store Finpecia tablets at room temperature (15-30°C or 59-86°F) in their original container, protected from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Properly discard any unused or expired medication according to local guidelines to prevent accidental exposure.
Disclaimer
This information is provided for educational purposes only and does not replace professional medical advice. Finpecia is a prescription medication that should only be used under the supervision of a qualified healthcare provider. Patients should discuss their medical history, potential risks, and treatment expectations with their physician before initiating therapy. Individual results may vary, and not all patients will experience hair regrowth.
Reviews
Clinical studies involving over 3,000 men demonstrated that 83% of Finpecia users maintained or increased hair count after two years of treatment, with 66% showing measurable improvement. Patient-reported outcomes indicate high satisfaction with treatment efficacy, though some report disappointment with the extent of regrowth. The most common reason for discontinuation remains concerns about potential sexual side effects, which affect approximately 3.8% of users in clinical trials compared to 2.1% in the placebo group. Long-term studies confirm that benefits are maintained with continued use, with no new safety concerns emerging during extended treatment periods.